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Background: Gastrointestinal stromal tumors (GISTs) represent a worldwide paradigm of
target therapy. The introduction of tyrosine kinase inhibitors has deeply changed the prognosis
of GIST patients, however, the majority of them acquire secondary mutations and progress.
Unfortunately, besides tyrosine-kinase inhibitors, no other therapeutic options are available.
Therefore, it is mandatory to identify novel molecules and/or strategies to overcome the
inevitable resistance. In this context, after promising preclinical data on the novel PI3K
inhibitor BYL719, the NCT01735968 trial in GIST patients who had previously failed treat-
ment with imatinib and sunitinib started. BYL719 has attracted our attention, and we compre-
hensively characterized genomic and transcriptomic changes taking place during resistance.
Methods: For this purpose, we generated two in vitro GIST models of acquired resistance to
BYL719 and performed an omic-based analysis by integrating RNA-sequencing, miRNA,
and methylation profiles in sensitive and resistant cells.
Results: We identified novel epigenomic mechanisms of pharmacological resistance in
GISTs suggesting the existence of pathways involved in drug resistance and alternatively
acquired mutations. Therefore, epigenomics should be taken into account as an alternative
adaptive mechanism.
Conclusion: Despite the fact that currently we do not have patients in treatment with
BYL719 to verify this hypothesis, the most intriguing result is the involvement of H19
and PSTA1 in GIST resistance, which might represent druggable targets.
Keywords: gastrointestinal stromal tumors, GIST, BYL719, PI3K inhibitor, tyrosine-kinase
inhibitors
Introduction
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors harboring
KIT/PDGFRA-driver mutations in 85%–90% of cases.1 GISTs are the example par
excellence of targeted therapy in solid tumors. Indeed, with the introduction of the
tyrosine-kinase inhibitor (TKI) imatinib, patients’ prognosis have dramatically
improved.2 Despite imatinib effectiveness, the majority of patients with advanced
GISTs have persistent measurable disease and eventually develop progressive
disease within 24–36 months.3 About 20 years after its approval, imatinib is still
the gold standard in GIST treatment. However, to cope with the emergence of
pharmacological resistance, the multi-TKIs sunitinib and regorafenib have been
introduced, as second- and third-line treatment, respectively, in GIST management.
Sunitinib and regorafenib share a mechanism of action with imatinib, adding
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clinical benefit to GIST patients after imatinib failure.
Even with clinical aids, the majority of patients experience
tumor progression, due to the emergence of multiple drug–
resistant KIT/PDGFRA mutations.4–9 Unfortunately, all the
approved treatments for GIST management are TKIs, and
to date there are no additional therapeutic options.
Therefore, the identification of novel druggable targets,
favored by better characterization of the resistance pro-
cess, may represent a key starting point to achieve
a different clinical approach. In this regard, a novel PI3K
inhibitor — BYL719 (Novartis) — is currently being
tested in a phase IB trial in GIST patients who have
previously failed imatinib and sunitinib
(NCT01735968).10 Specifically, BYL719 is a selective
inhibitor of the PI3K catalytic p110a subunit.11 Indeed,
the PI3K pathway, which is downstream of KIT/
PDGFRA receptors, is frequently activated in GIST and
thought to be related to imatinib resistance.12–16 Therefore,
PI3K-pathway inhibition represents an attractive target and
a promising strategy to counteract imatinib resistance in
GIST. In this study, we comprehensively characterized
genomic and transcriptomic changes taking place during
resistance and how GIST cells evolve from being drug-
sensitive to drug-resistant, from an “omic” point of view.
For this purpose, we generated two in vitro GIST models
of acquired resistance to BYL719 and performed an omic-
based analysis by integrating RNA sequencing, miRNA
profiling, and methylation profiling in sensitive and resis-
tant cells.
Methods
Cell culture and treatment
Two established human imatinib-resistant GIST cell lines,
GIST48 and GIST48B, were used (Table 1). These were
authenticated by KIT-sequencing and TKI-sensitivity
experiments, routinely grown in adhesion, and cultured at
37°C in a 5% CO2 humidified atmosphere. To generate
BYL719-resistant sublines, GIST48 and GIST48B were
exposed to increasing concentrations of BYL719 (Selleck
Chemicals, Houston, TX, USA), starting with
a concentration of 0.05 µM and increasing gradually to 5
µM. Fresh drug was provided every 3–4 days, when the
medium was replaced. After the cells had acquired the
ability to grow in the presence of a specific concentration
of BYL719, a proportion of them was frozen and the
remaining grown at the next-highest drug level. After
approximately 50 weeks, sublines of cells growing in 5
µM BYL719 were maintained continuously in culture at
this dose. Upon receipt and before each change of
BYL719 concentration, GIST lines were tested for myco-
plasma contamination and were found to be negative.
IC50: MTT-assay method
IC50 was evaluated by MTT assays using a standard
protocol.17 Briefly, 104 cells/well were seeded in triplicate
in a 96-well plate and incubated for 24 hours. After incu-
bation, the medium was removed and replaced with a fresh
one containing BYL719 in serial dilution and incubated
for 48 hours. Subsequently, cells were washed with PBS
and incubated with MTT (5 mg/mL) in PBS for 2 hours.
Following MTT removal, the formazan crystals were dis-
solved in isopropanol and absorbance measured at 570 nm
with a Tecan spectrophotometer (Spectra Model Classic,
Salzburg, Austria).
DNA and RNA isolation
Genomic DNA and total RNA were extracted from par-
ental (GIST48 and GIST48B) and BYL719-resistant
(GIST48-R and GIST48B-R) cultured cells using the
QIAamp DNA minikit and RNeasy minikit, respectively,
Table 1 GIST cell-lines a characteristics
Origin KIT mutations and other characteristics Growth
mediumb
GIST48 GIST
primary/
patientc
Primary, homozygous KIT exon 11 (V560D) mutation; secondary, heterozygous KIT exon 17
(D820Ad) mutation.
IMDM + 15%
FBS
GIST48B Subline of
GIST48
Retains primary mutation (KIT V560D) in all cells;
nearly undetectable KIT transcript and protein; secondary, heterozygous KIT exon 17 (D820Ad)
mutation; keeps downstream KIT signaling active
IMDM + 15%
FBS
Notes: aKindly provided by Dr Fletcher (Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA); breagents purchased from
Thermo Fisher Scientific (Waltham, MA); cestablished from a GIST patient that had progressed after initial response to imatinib therapy; dlocated in the kinase-activation
loop, confers resistance to imatinib and sunitinib.
Abbreviations: IMDM, Iscove's Modified Dulbecco's Medium; FBS, Fetal Bovine Serum.
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following manufacturer’s instructions. Both kits were pur-
chased from Qiagen (Hilden, Germany).
KIT and PI3KCA mutational analysis
Genomic DNA from parental and BYL719-resistant cell
lines was screened for the presence of hot-spot mutations
in KIT (exons 9, 11 13, 14, 17, and 18) and PI3KCA
(exons 9 and 20). Selected exons were amplified by PCR
using specific primers. Amplified PCR products were pur-
ified and sequenced on both strands using a Big Dye
Terminator version 1.1 cycle-sequencing kit (Thermo
Fisher Scientific). Sanger sequencing was performed on
an ABI 310 genetic analyzer (Applied Biosystems) and
analyzed using Chromas (Technelysium). Sequencing data
were analyzed using BLAST (https://blast.ncbi.nlm.nih.
gov/Blast.cgi) to match sequences with reference
sequences of KIT (NM_000222) and PI3KCA
(NM_006218) genes obtained from Ensembl genome
browser 94 (https://www.ensembl.org/index.html).
Western blot analysis
Whole-cell protein lysates were prepared from parental
and BYL719-resistant cell-monolayers using NP40 buffer
containing protease inhibitors (Halt protease- and phos-
phatase-inhibitor cocktail; Thermo Fisher Scientific) and
1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich).
Proteins were separated on SDS-PAGE and transferred
onto nitrocellulose membranes. Transfer efficiency was
demonstrated by Ponceau S staining (Sigma-Aldrich).
Membranes were blocked by 5% skimmed milk, followed
by incubation at 4°C overnight with the presence of
a primary antibody against KIT (A4502; Dako, Ely, UK),
phospo-KIT (3391; Cell Signaling Technology, Leiden,
Netherlands), AKT (9272; Cell Signaling Technology),
phospo-AKT (9271; Cell Signaling Technology), MAPK
(9102; Cell Signaling Technology), phospo-MAPK (9101;
Cell Signaling Technology), mTOR (2972; Cell Signaling
Technology), phospo-mTOR (2448; Cell Signaling
Technology), PTEN (138G6; Cell Signaling Technology),
and actin (A1978; Sigma-Aldrich). After rinsing, mem-
branes were incubated with horseradish peroxidase–con-
jugated secondary antibody (Thermo Fisher Scientific) at
room temperature for 2 hours. After further rinsing, immu-
noreactive bands were visualized by enhanced chemilumi-
nescence (BioRad, Hercules, CA, USA) and signals
captured and quantified using ChemiDoc (BioRad).
ABC transporter gene–expression
analysis
Total RNA was reverse-transcribed to cDNA using a high
capacity RNA-to-cDNA kit (Applied Biosystems) accord-
ing to the manufacturer’s instructions. cDNA was loaded
into a TaqMan human ABC-transporter array, which
allows quantitative gene-expression analysis of human
ABC-transporter genes important in drug discovery and
resistance. In particular, it contains assays in triplicate for
50 human genes and 14 endogenous controls in a 348-well
array. mRNA-expression levels were normalized using
GAPDH and 18S as endogenous controls, and data were
analyzed using the 2−ΔΔCt method. mRNAs with Ct>35
were considered unexpressed and excluded from further
analysis.
RNA sequencing (RNA-seq)
Whole-transcriptome RNA libraries were prepared in
accordance with the TruSeq RNA Sample Prep version
2 protocol (Illumina, San Diego, CA, USA). Poly(A)-
RNA molecules from 500 ng total RNA were purified
using oligo-dT magnetic beads. Subsequently, mRNA
was fragmented and randomly primed for reverse tran-
scription followed by second-strand synthesis to generate
double-stranded cDNA fragments. The cDNA fragments
generated went through a terminal end–repair process and
ligation using paired-end sequencing adapters. The
obtained products were amplified to enrich for fragments
carrying adapters ligated on both ends, and to add addi-
tional sequences complementary to the oligonucleotides
on the flow cell, thus creating the final cDNA library.
12pM paired-end libraries were amplified and ligated to
the flow cell by bridge PC and sequenced at 2×75bp read
length for RNA using Illumina sequencing-by-synthesis
technology.
RNA-seq : bioinformatic analysis
After demultiplexing and FASTQ generation, through the
bcltofastq function developed by Illumina, paired-end
reads were trimmed using AdapterRemoval (https://
github.com/MikkelSchubert/adapterremoval) with the aim
of removing stretches of low-quality bases (<Q10) and
Truseq/Nextera rapid-capture adapters present in the
sequences. Sequences coming from RNA-seqwere mapped
with TopHat/BowTie pipeline and PCR or optical dupli-
cates were removed with the function rmdup of SAMtools.
Dovepress Ravegnini et al
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RNA-seq: SNV calling
Single nucleotide variant (SNV) calling was performed
with SAMtools and SNVMix2, which allows the identifi-
cation of all point mutations and insertion/deletion var-
iants. Variants in the dbSNP, 1000 Genomes, ExAc, and
EVS databases with frequency >1% were excluded. The
possible functional effects of identified variants were ana-
lyzed with three in silico tools: SIFT, PolyPhen2, and
MutationTaster2.18–20
Gene-expression analysis
In order to compare gene-expression profile (GEP)
between BYL719-sensitive and -resistant GIST cell lines,
RNA-seq data were analyzed. After the alignment proce-
dure, the BAM file obtained was manipulated with
SAMtools to remove the optical/PCR duplicate and to
sort and index it. The HTSeq count (Python HTSeq pack-
age) was adopted to count the number of reads mapped on
known genes included in Ensembl 72 annotation features.
Functional annotation, GO, and pathway
analysis
NetworkAnalyst (https://www.networkanalyst.ca/faces/
home.xhtml) was used to identify molecular pathways
and functional groupings. Gene-interaction networks, bio-
function, and pathway analysis were generated using dif-
ferentially expressed genes (DEGs) into known functions,
pathways, and networks, primarily based on human stu-
dies. The DEGs were organized in Gene Ontology (GO)
biofunction and regulatory effect networks. Significance
was set at P<0.05. NetworkAnalyst uses a comprehensive
high-quality protein–protein interaction database based on
InnateDB. This database contains manually curated pro-
tein-interaction data from published literature, as well as
experimental data from several protein–protein interaction
databases, including IntAct, MINT, DIP, BIND, and
BioGRID. The database currently contains 14,755 proteins
and 145,955 interactions for humans.
qRT-PCR
Gene-expression levels of H19 and PSAT1 were evalu-
ated through quantitative reverse-transcription (qRT)
PCR. Briefly, RNA from both parental and BYL719-
resistant cell lines was reverse-transcribed to cDNA
using a high-capacity RNA-to-cDNA kit (Applied
Biosystems) according to the manufacturer's instructions.
qRT-PCR was performed with a Fast SYBR Green
Master Mix (Applied Biosystems) using the 7900HT real-
time PCR system. qRT-PCR assays for H19 and PSAT1
were performed using the primers H19-Fwd 5ʹ-
ATCGGTGCCTCAGCGTTCGG-3ʹ, H19-Rev 5ʹ-CTGTC
CTCGCCGTCACACCG-3ʹ, PSAT1-Fw 5ʹ-ATACAGA
GAATCTTGTGCGGG-3ʹ, PSAT1-Rev 5ʹ-CATAGTCAG
CACACCTTCCTG-3ʹ, GAPDH-Fwd 5ʹCGGGAAGCTT
GTCATCAAT-3ʹ, and GAPDH-Rev 5ʹ-GACTCCACGAC
GTACTCAGC-3ʹ. All primers were obtained from
Integrated DNA Technologies. Relative expression levels
were evaluated by the 2–ΔΔCt method using GAPDH as
a housekeeping gene.
miRNA-expression evaluation
Total RNA (300 ng) was reverse-transcribed using
a TaqMan miRNA reverse-transcription kit (Thermo
Fisher Scientific) using Megaplex RT primers Human
Pool A and Pool B. cDNAs were load on the TaqMan
arrays Human MicroRNA A and B Cards and run on
a 7900HT real-time PCR system in accordance with the
manufacturer's procedure. miRNA data were analyzed
with SDS relative quantification software version 2.4
(Applied Biosystems) and miRNAs with Ct>35 were con-
sidered unexpressed and excluded from further analysis.
miRNA-expression levels were normalized using U6 and
RNU48 as endogenous controls. Normalization was car-
ried out by subtracting the mean Ct from individual Ct
values. R-Bioconductor (package Limma) was adopted to
evaluate differential expression profiles between the par-
ental and BYL719-resistant GIST cell lines.
Global methylation profile
Genomic DNA (600 ng/sample) were bisulfite-converted
using EZ DNA methylation kits (Zymo Research), and
DNA methylation was measured using the Illumina
Infinium HD-methylation assay with Infinium Methylation
Epic BeadChips according to Illumina's protocol. Raw data
(Idat files) were processed in R Bioconductor (minfi27). The
quality of each sample was analyzed and probe signals
removed when: i) P>0.05; ii) >1% of the data set contained
no data; or iii) probes contained single-nucleotide poly-
morphisms. None of the samples included in the study was
flagged as an outlier.21 Statistical analyses were carried out
using GenomeStudio, normalizing Idat values with controls
provided by Illumina. The methylation score of each CpG is
represented as a β-value, and differences between β-values of
treated and untreated cells represent alterations in methyla-
tion level. The CpGs selected were those with absolute
Ravegnini et al Dovepress
submit your manuscript | www.dovepress.com
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methylation differential value of >0.2 or <–0.2.21,22 To iden-
tify CpGs on promoter regions, we considered only UCSC
reference-gene groups TSS200 or TSS1500.
Identification of validated miRNA targets
Targets of significant miRNAs were identified through
specific in silico tools that allowed prediction of the most
probable targets. Specifically, to limit false-positive
results, we used the miRTarBase tool, which encloses
more than 400,000 miRNA-target experimentally verified
interactions, collected by manually surveying pertinent
literature after systematic data mining of the text.
miRNA-profile and gene-expression
correlation
miRNA and mRNA arrays were analyzed to highlight pairs
of mRNAs and miRNAs that were discordant (up- versus
downregulated and vice versa). Potential miRNA–mRNA
interactions and miRNA/mRNA-expression profiles were
used to construct functional interaction networks.
Methylation-profile and gene-expression
correlation
To integrate methylation profiles and GEP, we considered
only CpGs on promoter regions that shown absolute
methylation differentials of >0.2 or <–0.2 in parental
lines versus BYL719-resistant ones. Promoter regions
were defined as upstream 1,500 bp and downstream 200
bp from the transcription-start site (TSS) of each gene. For
each differentially methylated gene, we checked the
expression level derived from RNA sequencing.
Results
MTT assay
GIST48 and GIST48B cell lines were exposed to BYL719
using doses that were increased in a stepwise manner. We
thus established two BYL719-resistant GIST cell lines (48-R
and 48B-R), which exhibited BYL719 IC50 values that were
about 15-fold higher than the parental cell lines (Figure S1).
KIT and PI3KCA mutational analysis
The involvement of KIT and PI3KCA mutations as mechan-
isms driving BYL719 resistance in GIST cells in vitro was
investigated. Mutational analysis did not reveal additional
KIT mutations in BYL719-resistant cell lines by Sanger
sequencing or SNV calling. With regard to PI3KCA, we
Sanger sequenced exons 9 and 20, both codifying for the
catalytic p110a subunit and associated with drug
resistance.23–26 All samples were wild type. PI3KCA wild-
type status was also confirmed by SNV calling.
Western blot analysis
To better characterize the BYL719-resistant GIST48-R
and GIST48B-R lines, we performed Western blot analy-
sis, evaluating in particular the signaling pathway down-
stream of KIT (Figure 1A). In the imatinib-resistant
GIST48 line (as expected, considering that the targeted
PI3K is downstream of KIT), we observed comparable
KIT phosphorylation between GIST48 and GIST48B-R
(Figure 1B). Absence of KIT phosphorylation was
observed, as expected, in both GIST48B and GIST48B-
R. Indeed this GIST model had entirely lost KIT expres-
sion (ie, KIT-negative, despite activation of downstream
signaling [Figure 1C]). No differences were observed in
PTEN status between parental and BYL719-resistant cell
lines. On the contrary, in both GIST models, we detected
activated AKT in BYL719-sensitive cell lines and inacti-
vation in the resistant ones. We also observed activation of
mTOR in both parental and BYL719-resistant cell lines.
Finally, we observed MAPK activation in both BYL-
sensitive and -resistant GIST models. All immunoblots
are shown in Figure 1, B and C.
RNA-seq: SNV calling
We identified ten novel mutations in BYL719-resistant
cells compared to parental cell lines. In particular, four
mutations were identified in GIST48-R cells and six in
GIST48B-R (Table 2). None of the mutations was com-
mon to both the two resistant GIST cell lines. With regard
to GIST48-R, one mutation was identified as benign
(KIFC2) and one probably damaging (RPGR) by the
three tools. One mutation (RIF1) was predicted as prob-
ably damaging by two tools. Lastly, no agreement was
reached for one mutation (DPF1). Concerning GIST48B-
R, one mutation (FRY) was predicted as probably dama-
ging by the three tools, two mutations (PDGFB and
SYT14) were identified as benign by two tools, and no
agreement was reached for two mutations (DCHS1 and
EEF2KMT). Lastly, one mutation (RARS2) was a gain of
stop codon. Data are reported in Table 2. However, none
of them was related to the PI3KCA pathway, had been
previously identified in GIST, or associated with resistance
in other tumor types; therefore, we did not consider them
driver mutations for BYL719 resistance.
Dovepress Ravegnini et al
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Gene expression: ABC-transporter genes
and RNA-seq analysis
Given the well-recognized role of ABC-transporter
genes in mediating drug resistance, first we analyzed
a custom panel of 50 genes in BYL719-sensitive and -
resistant GIST lines. None was significantly deregu-
lated. Therefore, we performed a RNA-seq analysis,
which showed 95 differentially expressed genes with
P≤0.001 and a false discovery rate <0.1 in BYL719-
sensitive compared to BYL719-resistant GIST lines. In
particular, 48 genes were upregulated, while 47 were
downregulated. The significant DEGs are reported in
Table S1. The 20 top deregulated genes — 13 up- and
7 downregulated — are shown in Figure 2A. GO func-
tional enrichment analyses of deregulated genes
showed cancer, chronic myeloid leukemia, and cell
cycle as the top three deregulated pathways (Kyoto
Encyclopedia of Genes and Genomes pathways
(KEGG), Figure 2B). In addition, we found viral repro-
ductive process and viral reproduction to be the top
biological processes involved. RNA binding, structural
constituents of ribosome, and structural molecular
activity were the top three molecular functions.
Finally, cytosol, macromolecular complex, and ribonu-
cleoprotein complex were the top three cellular com-
ponents involved. Interestingly, among the top
upregulated genes in resistant cells, there was the
long non coding RNA (lncRNA) H19. RNA-seq data
were confirmed by qRT-PCR, which demonstrated
overexpression of H19 in GIST48-R and GIST48B-R
compared with the parental BYL719-sensitive lines,
with fold changes of 20.8 and 6.9, respectively.
Table 2 Acquired mutations in BYL719-resistant GIST cells
GIST 48 vs GIST48-R GIST 48B vs GIST48B-R
Gene Exon AA change Prediction* Gene Exon AA change Prediction*
DPF1 9 p.C313G Ba, PDc DCHS1 2 p.R168C Ba, PDb,c
KIFC2 17 p.R732C Ba–c EEF2KMT 2 p.H52Q Ba,b, PDc
RIF1 19 p.V666A PDa,c FRY 5 p.D168Y PDa–c
RPGR 6 p.Q171R PDa–c PDGFB 3 p.R51H Ba,c
RARS2 1 p.C11X Gain of stop codonb
SYT14 6 p.V359A Bb,c
Note: *Prediction of the deleterious potential through aSIFT, bPolyPhen, and cMutationTaster2.
Abbreviations: AA, amino acid; B, benign; PD, probably damaging.
MTOR
Survival
Proliferation
Differentiation
MEK
RAF
RAS
GIST48
S
AKT
KIT
phospoKIT
phospoKIT
phosphoMTOR
phospoMAPK
PTEN
MTOR
MAPK
Actin
SR R
GIST48B
A B C
MAPK
AKT
PTEN
PI3K
BYL719
P P
Figure 1 Western blot analysis.
Notes: (A) Simplified KIT-signaling pathway. Immunoblot evaluation of KIT, phospho-KIT, PTEN, AKT, phospho-AKT, mTOR, phospho-mTOR, MAPK, and phospho-MAPK in
GIST48 (B) and GIST48B (C). S, BYL719-sensitive; R, BYL719-resistant.
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miRNA-expression profile
The array highlighted a total of 44 deregulated miRNAs of the
754 analyzed (P<0.05); however, after adjustment, only 13
miRNAs maintained statistical significance. In particular, two
miRNAs— has-miR190b and has-miR299-5p— were upre-
gulated and eleven miRNAs downregulated in resistant GIST
cell lines compared to parental ones. All differentially
expressed miRNAs are reported in Table 3. Hierarchical clus-
tering of all samples dichotomized sensitive and resistantGIST
cell lines into two distinct clusters (Figure 3A). Through
miRPath 3.0, we assessed miRNA regulatory roles and
identification of controlled pathways.27 Interestingly, among
the pathways potentially modulated by the deregulated
miRNAs (summarized in Figure 3B), the most significant
and those with the greatest number of target genes were
PI3K/AKT, MAPK, and RAS cascades, which are involved
in BYL719's mechanism of action. Figure 3C shows the main
miRNAs involved in cancer (highlighted in blue) and PI3K–
AKT (in green) and JAK–STAT (in pink) pathways. In parti-
cular, among the 13 deregulated miRNAs retrieved by our
data,we identified a signature offivemiRNAsmainly involved
in the aforementioned pathways: miR22-3p, miR125b-5p,
miR149-3p, miR190b, and miR520c-3p.
Global methylation profile
To determine whether acquired resistance involved mod-
ifications in DNA methylation, we performed genome-
wide DNA-methylation profiling in BYL719-sensitive
and -resistant GIST cell lines. We identified 3,305 differ-
entially methylated CpGs. Among these, 2,817 were
hypermethylated and 488 hypomethylated. Of the hyper-
methylated CpGs, 547 were in promoter regions of 379
genes, while 102 hypomethylated sites were in promoter
regions of 70 genes. Unsupervised hierarchical cluster
analysis of the demethylated genes divided the sensitive
and resistant cell lines into two main clusters (Figure 4).
Interestingly, as shown in Figure 5, A–C, the resistant cells
showed significantly more hypermethylated CpG-island
promoters compared to the sensitive counterparts.
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Abbreviations: GIST, gastrointestinal stromal tumors; GO, gene ontology.
Table 3 The most significantly deregulated miRNAs
miRNA P-value Adjusted
P-value
hsa-miR1243 2.94–6 0.002232799
hsa-miR520c-3p 1.27–5 0.003316809
hsa-miR190b 1.31–5 0.003316809
hsa-miR1289 2.72–5 0.005164803
hsa-miR1247-5p 0.000118 0.016017348
hsa-miR22-3p 0.000126 0.016017348
hsa-miR1267 0.000188 0.020418143
hsa-miR299-5p 0.000237 0.022470219
hsa-miR125b-5p 0.000294 0.024789505
hsa-miR656-3p 0.000447 0.033993852
hsa-miR331-5p 0.000591 0.040837133
hsa-miR149-3p 0.000868 0.054998185
hsa-miR30d-5p 0.001126 0.065812471
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miRNAs and mRNA network
To construct miRNA–DEG networks, we downloaded the
experimentally verified associations between human
miRNAs and their targets from miRTarBase. This data set
consists of 4,076miRNAs and 23,054mRNAs,28 and encloses
more than 400,000 miRNA–target interactions collected by
manually surveying pertinent literature after systematic data
mining of the text. Among the 13 deregulated miRNAs
retrieved by our data, seven (miR331-5p, miR125b-5p,
miR520c-3p, miR1289, miR299-5p, miR30d-5p, and
miR149-3p) had verified associations with their targets.
However, taking into account the canonical inverse correlation
between miRNA and target expression, we were able to iden-
tify eight mRNA–miRNA networks. In particular, we found
G
IS
T4
8
-5.0 0.0 5.0
-0
.9
81
28
09
-0.99282813
0.00358559346
1.0 0
hsa-mir-
149-3b
hsa-mir-
520c-3p
Pa
thw
ay
s i
n c
an
ce
r
PI
3K
-A
kt 
sig
na
lin
g p
ath
wa
y
MA
PK
 si
gn
ali
ng
 pa
tw
ay
Ra
s s
ign
ali
ng
 pa
thw
ay
En
do
cy
tos
is
Ra
p1
 si
gn
ali
ng
 pa
thw
ay
Pr
ote
og
lyc
an
s i
n c
an
ce
r
Tra
ns
cri
pti
on
al 
mi
sre
gu
lat
ion
 in
 ca
nc
er
Ax
on
 gu
ida
nc
e
Pr
ote
in 
pro
ce
ss
ing
 in
 en
do
pla
sm
ic 
ret
icu
lum
20N
um
be
r o
f t
ar
ge
t g
en
es
40
60
80
100
120
140
hsa-miR-190b
hsa-miR-1243
hsa-miR-520c-3p
hsa-miR-1285
hsa-miR-1267
hsa-miR-125b-5p
hsa-miR-22-3p
hsa-miR-656-3p
hsa-miR-331-5p
hsa-miR-1247-5p
hsa-miR-149-3p
hsa-miR-299-5p
0.
00
93
59
53
9
1.
0
G
IS
T4
8-
R
G
IS
T4
8B
G
IS
T4
8B
-R
A
B
 C
hsa-mir-
190b
Figure 3 miRNAs profile .
Notes: (A) miRNA hierarchical clustering. miRNAs identified as differentially expressed between BYL719-sensitive and -resistant GIST cell lines were selected as markers
for unsupervised hierarchical clustering. (B) GO functional enrichment analysis of up- and downregulated miRNAs. (C) Main miRNAs involved in cancer (blue), AKT–mTOR
(green) and JAK signaling cascades (pink) pathways.
Ravegnini et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Cancer Management and Research 2019:116236
 
Ca
nc
er
 M
an
ag
em
en
t a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
20
4.
23
4.
57
 o
n 
19
-J
ul
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
four miRNAs downregulated and the corresponding seven
targets overexpressed (three miRNAs targeted two distinct
mRNAs). OnemiRNAwas upregulated and the corresponding
target downregulated. The miRNAs and their corresponding
targets are presented in Figure 6.
DNA methylation and mRNA network
To clarify the relationship between DNA methylation and
differentially expressed mRNAs, we integrated the global
methylation profile with DEGs. Results are shown in
Figure 7. Among the genes with the strongest promoter
hypermethylation and concomitant increased expression in
resistant cells were CLMN, a member of the hedgehog-
interacting protein family MAL, which encodes the
T-lymphocyte maturation-associated protein and functions
in T-cell differentiation. On the contrary, promoter hyper-
methylation and concomitant TSHZ2 downregulation was
observed, whereas PSAT1 showed strong promoter
hypomethylation associated with increased gene expression
after treatment. Overexpression of PSAT1 was confirmed by
qRT-PCR, which demonstrated overexpression of PSAT1 in
GIST48-R and GIST48B-R compared with the parental
BYL719-sensitive lines, with fold changes of 4.1 and 5.8,
respectively.
Construction of the miRNA–mRNA–
DNA methylation network
In order to identify a more comprehensive network, we
integrated data deriving from GEP, miRNA, and methyla-
tion profiles. After intersection of all the data, the PSAT1
gene was significantly upregulated in BYL719-resistant
cell lines and showed promoter hypomethylation and
a potential modulation by miR125b-5p (Figure 7).
Discussion
GISTs represent a worldwide paradigm of target therapy.
The introduction of imatinib to clinical practice has deeply
revolutionized its management, leading GISTs from an
incurable disease to a sort of chronic disease. Imatinib
has determined terrific improvement in GIST prognosis;
however, as often happens with TKIs, the majority of
patients acquire secondary mutations and the disease pro-
gresses. Unfortunately, no therapeutic options are available
for patients who have failed on imatinib and the subse-
quent therapeutic lines: sunitinib and regorafenib.
Therefore, it is pivotal and mandatory to identify novel
molecules — different from TKIs — and/or strategies to
overcome the inevitable resistance. In this context, after
the promising preclinical data on the novel PI3K inhibitor
BYL719,10 the NCT01735968 trial in GIST patients who
had previously failed treatment with imatinib and sunitinib
started. BYL719 attracted our attention, and we compre-
hensively characterized genomic and transcriptomic
changes taking place during resistance. Understanding
how GIST cells evolve from being drug-sensitive to drug-
resistant, from an omic point of view might accelerate the
identification of novel druggable targets. For this purpose,
we generated two in vitro GIST models of acquired resis-
tance to BYL719 and performed an omic-based analysis
by integrating RNA-seq, miRNA, and methylation profil-
ing in sensitive and resistant cells. In particular, we
selected GIST48 and GIST48B, sharing activation of KIT
downstream signaling, including the PI3K pathway, tar-
geted by BYL719.29 Furthermore, both cell lines are resis-
tant to the second-line treatment sunitinib,30 making them
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Figure 4 Global methylation profile.
Notes: Heat map showing DNA-methylation profiles in parental and BYL719-
resistant cell lines (Δβ<–0.2 or >0.2).
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good models, mirroring GIST patients who hypothetically
will receive BYL719 treatment after imatinib and sunitinib
failure.
TKI resistance is largely due to accumulation of addi-
tional kinase-domain mutations.31 Therefore, we sequenced
KIT and PI3KCA hot-spot exons — in addition to RNA-
seq — to evaluate the appearance of novel point mutations
or insertion/deletion variants possibly able to explain
BYL719 resistance. Different alterations were found in
BYL719-resistant lines; however, none was shared by
both models, or harbored in PI3KCA and KIT genes, or
downstream effectors. In addition, none of the mutated
genes has been involved in drug resistance; therefore, we
did not consider them driver events for BYL719 unrespon-
siveness, pinpointing a potential novel mechanism of resis-
tance in GISTs. Afterward, we analyzed a precast panel of
50 well-characterized ABC-transporter genes.
Overexpression of genes involved in drug efflux is among
the most common mechanisms of drug resistance.32–34
However, we did not observe any significant difference in
BYL719-resistant cell lines compared to sensitive ones.
This prompted us to perform a more comprehensive gene-
expression analysis through the RNA-seq approach. We
identified the H19 gene as one of the most significantly
upregulated in BYL719-resistant cells compared to sensi-
tive ones. H19 has been described as an oncogenic lncRNA
involved in cell proliferation, metastasis, epithelial–
mesenchymal transition, and poor prognosis in several can-
cer types, including esophageal squamous-cell carcinoma,
osteosarcoma, colorectal and gastric cancer, and others.35–38
A recent study reported H19 overexpression in GIST
samples compared to normal paired tissue.39 In addition,
H19 upregulation showed a high correlation with ETV1
expression, which is crucial in GIST growth and survival.
ETV1 cooperates with KIT through the MAPK-signaling
pathway, and together they promote GIST
tumorigenesis.40 Furthermore, it has been reported that
H19 might promote migration and invasion in colorectal
cancer by activating the RAS protein and upregulating
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Figure 6 Integrated miRNA–mRNA regulatory networks.
Notes: Integration of GEP and miRNA profiles. Circles and squares represent
genes and miRNAs, respectively. Red and green indicate downregulation and upre-
gulation, respectively.
Abbreviation: GEP, gene expression profile.
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levels of phospho-RAF, phospho-MEK and phospho-
MAPK.41 Considering that RAS is upstream of both the
PI3K and MAPK pathways,42 this could represent an
alternative mechanism through which resistant cells
bypass PI3K and maintain their tumorigenic status. This
assumption was confirmed by Western blot analysis, high-
lighting MAPK activation in both parental and BYL719-
resistant cell lines. Interestingly, we also observed a weak
activation of mTOR in BYL719-resistant cell lines, despite
no AKT activity. This finding agrees with the recognized
complex and dynamic cross talk between PI3K/AKT and
MAPK.43,44 Pathway cross talk allows a cell to achieve
robust activation of key downstream targets or compensa-
tory signaling. Particularly, the latter might be important in
the context of drug resistance, allowing growth and viabi-
lity of cancer cells. Indeed, combined inhibition of PI3K–
Akt and MAPK pathways has shown efficacy in preclini-
cal models,43–46 and could be of interest in the manage-
ment of imatinib-resistant GISTs.
Considering the lack of acquired PI3KCA muta-
tions, we further evaluated the hypothesis that
BYL719 resistance could be mediated by epigenetic
mechanisms. Studies reported that epigenetic modifica-
tions may represent alternative mechanisms to evade
the pharmacological response.47–49 In this context, dif-
ferent trials are evaluating epigenetic therapies as drug-
resistance modulators in solid tumors.47 With regard to
GISTs, in recent years epigenetic treatments raised
among the future perspective50,51 alternatively to
TKIs and/or to bypass TKI resistance. However, the
results are still at an early stage, and further investiga-
tions are essential in this novel field. Consequently, we
performed deep epigenomic characterization of these
two in vitro models, looking for novel mechanisms of
acquired resistance and potential druggable targets in
GISTs. For this purpose, we performed miRNA profil-
ing, identifying 13 miRNAs significantly deregulated in
resistant cells. Among the pathways potentially modu-
lated by these miRNAs, the most significant and those
with the greatest number of target genes were PI3K/
AKT–MAPK, and RAS cascades, which are involved
in BYL719's mechanism of action. Subsequently, inte-
gration of miRNA arrays and GEP revealed five
miRNAs targeting eight genes (TRIB1, GAB2, SNX10,
SAMD12, JUNB, GPC3, and SOX4). Among those
genes, TRIB1 is a downstream effector of PI3K, and
GAB252 cooperates with the PI3K–AKT pathway in
promoting malignant behavior in cells.53,54
/CLMN
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Figure 7 Integrated miRNA–mRNA–methylation regulatory networks.
Notes: Integration of GEP, miRNA, and methylation profiles. In gray are shown genes and miRNAs with the same trend of expression, which were excluded. Red and green
indicate downregulation and upregulation, respectively.
Abbreviation: GEP, gene expression profile.
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Subsequently, we integrated methylation and GEP, iden-
tifying two networks of interest involving TSHZ2 and
PSAT1. The TSHZ2 gene resulted in downregulated
BYL719-resistant cells compared to sensitive ones.
TSHZ2, a zinc-finger homeobox nuclear protein, is sup-
posed to be a tumor suppressor and is downregulated in
breast cancer.55 We speculated that TSHZ2 might bind
transcriptional regulators that control the expression of cru-
cial genes in tumorigenesis and resistance acquisition.
Moreover, PSAT1 was upregulated in BYL719-resistant
cells, and concomitant hypomethylation on the PSAT1 pro-
moter was found. However, on integration of miRNA and
methylation profiles with gene-expression analysis, we pin-
pointed overexpression of PSAT1 associated with both pro-
moter hypomethylation and miR125b-5p downregulation.
In particular, PSAT1 overexpression in BYL719-resistant
cell lines could represent an advantage for resistant cells,
which have to find novel ploys to live.
Here, we showed that both methylation and miRNA
modulated PSAT1 overexpression. Additional studies are
needed to clarify if the epigenetic mechanisms act concur-
rently or in a mutual manner, with the final goal of increas-
ing PSAT1 levels, which confer a metabolic-related growth
advantage to tumor cells. PSAT1 overexpression is involved
in drug resistance in different tumors, including colorectal
cancer, melanoma, pancreatic cancer, and non-small-cell
lung cancer.56,57 PSAT1 belongs to the serine biosynthesis
pathway, which has a key role in nucleotide and amino-acid
metabolism. Levels of enzymes involved in serine synthesis
have been shown to increase under conditions of DNA
damage and genomic instability.57,58 In addition, a recent
study reported that serine supports one-carbon metabolism
and proliferation of cancer cells.59 Moreover, different evi-
dence suggests that the serine pathway is crucial in cancer
metabolism, using glycolysis-derived glucose for serine
production and tumor growth.60–64 In addition to these
studies, which clearly ascribed to PSAT1 a role in tumor-
igenesis, a recent study on esophageal squamous-cell carci-
noma patients linked PSAT1 overexpression to upregulation
of the PI3K–AKT–GSK3β–Snail pathway.65 Therefore, tar-
geting PSAT1 might have potential therapeutic implication
in GIST patients.
In conclusion, we identified novel epigenomic mechan-
isms of pharmacological resistance in GISTs, suggesting
the existence of pathways involved in drug resistance and
alternative to acquired mutations. We are aware that pro-
longed exposure and high BYL719 concentrations used to
generate the resistant models can be de facto a substantial
source of numerous off-target effects. However, prolonged
inhibition of the PI3K pathway is probably accompanied
by profound transcriptomic, proteomic, and metabolomic
changes involved in drug resistance. Therefore, epige-
nomics should be taken into account as an alternative
adaptive mechanism. Currently we do not have access to
GIST patients in treatment with BYL719, and thus we are
not able to verify the hypothesis in vivo. However, we
consider these results intriguing, particularly the involve-
ment of H19 and PSTA1 in GIST resistance, which might
represent novel druggable targets for GIST patients.
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Table S1 List of genes differentially expressed in parental and resistant cell lines
Upregulated genes in BYL719-resistant cell lines Downregulated genes in BYL719-resistant cell lines
LogFC P-value FDR LogFC P-value FDR
H19 2.23 8.61–12 1.08–7 C16ORF89 −2.21 0 0.000001
RAB3IP 3.23 1.19–9 3.93–6 MXRA5 −1.90 0 0.000004
ANXA3 1.81 8.24–8 0.000148 BRINP1 −3.82 0 0.000121
LXN 2.57 2.9–7 0.000304 CUX2 −2.27 0 0.000215
CHAC1 2.41 1–6 0.000841 SLC4A7 −1.57 0 0.000215
TNFSF10 3.12 1.53–6 0.001043 PCSK6 −1.78 0 0.000215
CLMN 2.40 1.8–6 0.001078 SGK1 −2.46 0.000001 0.000535
ACSM3 2.26 5.71–6 0.002987 GPC2 −1.79 0.000001 0.001010
PDE5A 1.52 9.67–6 0.004328 FN1 −1.54 0.000003 0.001451
DSG2 2.60 1.39–5 0.005618 RHBDF1 −1.43 0.000007 0.003245
ASNS 1.30 1.58–5 0.00619 SAMD11 −1.38 0.000008 0.003622
PSAT1 1.48 1.96–5 0.007033 VCAM1 −1.67 0.000017 0.006486
SNX10 2.00 2.51–5 0.008495 ID3 −1.69 0.000019 0.006898
LMO4 1.29 2.64–5 0.008495 SMAD9 −1.28 0.000029 0.008963
SEMA3C 2.39 3–5 0.009034 SLC14A1 −3.15 0.000030 0.009034
GLRB 2.02 3.22–5 0.009306 TSHZ2 −2.18 0.000033 0.009306
ADD2 1.62 4.99–5 0.012541 MME −1.47 0.000035 0.009897
EGR1 2.46 7.05–5 0.017026 RP11-54O7.1 −2.01 0.000041 0.010885
MAL2 2.82 7.84–5 0.017893 PHF2P2 −1.39 0.000042 0.011066
PRIMA1 2.06 8.88–5 0.018896 TYRO3 −1.42 0.000097 0.019908
TBC1D2B 1.47 9.25–5 0.019348 NUAK1 −1.45 0.000105 0.020765
GAB2 2.19 0.000108 0.020816 PHLDB2 −1.64 0.000106 0.020765
PROCR 1.89 0.000129 0.023094 DACT3 −1.43 0.000104 0.020765
ICA1 2.05 0.000132 0.023302 GTF2IP3 −2.01 0.000109 0.020816
PRKCQ-AS1 1.56 0.000142 0.024358 ID2 −1.25 0.000117 0.021688
DOCK9 1.77 0.000171 0.0276 EFNB2 −1.59 0.000137 0.023811
LAMP3 1.22 0.000232 0.035097 IQGAP2 −1.14 0.000144 0.024358
TRIB1 1.25 0.000232 0.035097 RBM18 −1.17 0.000170 0.027600
TBC1D8B 1.62 0.000266 0.038374 SOSTDC1 −1.84 0.000189 0.030100
SFRP1 1.10 0.000358 0.048283 F2R −1.48 0.000225 0.034926
TNFAIP8 1.29 0.000407 0.052689 ADGRD1 −1.54 0.000262 0.038374
SAMD12 2.06 0.000424 0.053714 GAREM −1.46 0.000297 0.042399
JUNB 1.43 0.000444 0.055782 SOX4 −1.23 0.000306 0.043207
DAAM2 1.21 0.000483 0.05878 SMAD6 −1.21 0.000350 0.047754
IGSF3 1.13 0.000487 0.05878 SH3BP5-AS1 −1.66 0.000347 0.047754
LGI2 1.90 0.000521 0.061597 PREX2 −1.06 0.000369 0.049242
CALB2 1.72 0.000525 0.061597 BCRP3 −1.76 0.000420 0.053714
PDE3B 1.39 0.000552 0.063588 COL16A1 −1.15 0.000449 0.055782
GPC3 1.71 0.000574 0.064953 PDLIM3 −1.45 0.000463 0.056947
TNFRSF19 2.17 0.000571 0.064953 ADAMTS2 −1.65 0.000512 0.061195
FOXP2 1.57 0.00061 0.06843 WTIP −1.16 0.000531 0.061674
BST2 1.18 0.000619 0.068795 MYO1B −1.27 0.000626 0.068960
HUNK 1.30 0.000647 0.070631 SORBS1 −1.55 0.000703 0.075396
FAM19A4 1.76 0.000709 0.075396 PPARGC1B −1.01 0.000794 0.081682
ARRB1 1.27 0.000737 0.07712 ATOH8 −2.31 0.000808 0.082507
CCDC181 1.55 0.000893 0.088251 ZDHHC11 −1.33 0.000832 0.084194
GLTSCR2 0.98 0.001004 0.098527 CTGF −1.16 0.000869 0.087235
FOS 2.77 0.001014 0.098663
Abbreviation: FDR, fold discovery rate.
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Figure S1 MTT assay.
Notes: Cell viability in GIST48 and GIST48B (red curves) and BYL719-resistant counterparts (blue curves).
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